DiaMedica Therapeutics Inc. (DMAC)
$5.46
$0.13
(2.44%)
As on 11-Jun-2026 16:00EDT
Market cap
$304 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.4
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
53,883,345
10 Years Aggregate
CFO
$-78.52 Mln
EBITDA
$-90.27 Mln
Net Profit
$-88.07 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
DiaMedica Therapeutics (DMAC)
| -31.4 | -13.6 | -31.3 | 32.5 | 20.3 | -8.0 | 4.9 |
|
BSE Sensex*
| -12.0 | -2.0 | -3.0 | -9.7 | 6.0 | 7.3 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
DiaMedica Therapeutics (DMAC)
| 46.6 | 79.7 | -57.6 | -63.2 | 109.1 | 66.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
DiaMedica Therapeutics (DMAC)
|
5.5 | 303.9 | 0.0 | -35.1 | 131,201.1 | -71 | -- | 6.4 |
| 5.3 | 1,716.2 | 79.2 | -144.0 | -259.5 | -15.1 | -- | 2.1 | |
| 15.9 | 2,037.1 | 298.3 | 298.2 | 47.7 | 63.9 | 7.3 | 3.7 | |
| 5.7 | 48.6 | 0.1 | -10.4 | -20,782.3 | -92.2 | -- | 34.6 | |
| 8.9 | 302.2 | 51.0 | -8.4 | -13.3 | -- | -- | 8.4 | |
| 1.6 | 5.2 | 663.9 | -9.9 | -1.5 | -86 | -- | 0.8 | |
| 1.3 | 153.1 | 1.8 | -68.4 | -3,544.8 | -241.8 | -- | 4.4 | |
| 52.2 | 5,000.5 | 0.0 | -383.2 | -- | -40.4 | -- | 3.7 |
Shareholding Pattern
View DetailsAbout DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue... kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Read more
-
President, CEO & Director
Mr. Dietrich John Pauls MBA
-
President, CEO & Director
Mr. Dietrich John Pauls MBA
-
Headquarters
Minneapolis, MN
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for DiaMedica Therapeutics (DMAC)
What is the current share price of DiaMedica Therapeutics Inc (DMAC) Today?
The share price of DiaMedica Therapeutics Inc (DMAC) is $5.46 (NASDAQ) as of 11-Jun-2026 16:00 EDT. DiaMedica Therapeutics Inc (DMAC) has given a return of 20.25% in the last 3 years.
What is the current PB & PE ratio of DiaMedica Therapeutics Inc (DMAC)?
Since, TTM earnings of DiaMedica Therapeutics Inc (DMAC) is negative, P/E ratio is not available.
The P/B ratio of DiaMedica Therapeutics Inc (DMAC) is 6.41 times as on 05-Jun-2026, a 57 premium to its peers’ median range of 4.08 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-11.42
|
6.67
|
|
2024
|
-8.89
|
5.33
|
|
2023
|
-4.84
|
1.84
|
|
2022
|
-3.00
|
1.29
|
|
2021
|
-5.76
|
1.78
|
What is the 52 Week High and Low of DiaMedica Therapeutics Inc (DMAC)?
The 52-week high and low of DiaMedica Therapeutics Inc (DMAC) are Rs 10.42 and Rs 3.48 as of 12-Jun-2026.
What is the market cap of DiaMedica Therapeutics Inc (DMAC)?
DiaMedica Therapeutics Inc (DMAC) has a market capitalisation of $ 304 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in DiaMedica Therapeutics Inc (DMAC)?
Before investing in DiaMedica Therapeutics Inc (DMAC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.